한국지질동맥경화학회 학술대회

TBD

TBD

TBD

Interplay between molecular and environmental factors in the new era of precision medicine

Human microbiome and the path to cardiometabolic health

Iron overload, autophagy dysfunction, and ferroptosis: mechanistic insights into cardiometabolic disease

Epidemiologic evidence on Lp(a) and ASCVD in Asian populations

The inverse link between Lp(a) and metabolic risk: signal or noise?

Lp(a) testing today: mind the method, mind the unit

From nanoparticles to biocides: how toxic chemicals alter lipid homeostasis and accelerate atherosclerotic events

Immune modulation of lipid metabolism promotes BAT whitening under thermoneutral conditions

Role of MCU in human platelet aggregation

Coronary atherosclerosis and cardiovascular risk prediction through AI-assisted stress echocardiography: insights from the PROTEUS RCT trial

AI-enhanced ECG for acute myocardial infarction detection and cardiovascular risk stratification

Artificial intelligence-based coronary artery disease screening versus usual care for patients with suspected coronary artery disease: AI-Gatekeeper randomized controlled trial

CVD risk prediction in low-risk population

CVD risk prediction in older persons

CVD risk prediction in diabetes and high-risk patients

Deep dive into PCSK9: the master regulator of LDL metabolism and inflammation

siRNA-based lipid therapies: a revolution in cholesterol management

Novel strategies for familial hypercholesterolemia management beyond statins

Prediction of ASCVD using the TyG index: insights from the multinational PURE registry

Prediction of ASCVD using the TyG index: evidence from Korean data

Prediction of coronary artery calcification progression using the TyG index

Beyond statins: advances in FH management

Early detection of FH: role of genetic screening and cascade testing

Cardiovascular risk in FH: how early is early enough for intervention?

LDL-C targets for patients with diabetes across major guidelines

Pro: all patients with diabetes should be treated to LDL-C <55 mg/dL?

Cons: LDL-C targets should be personalized in diabetic patients?

Mechanisms linking socioeconomic status and cardiovascular risk

Epidemiologic evidence on socioeconomic status and cardiovascular outcomes

New models for CVD risk assessment: incorporating socioeconomic data

The cardio-renal-metabolic vicious cycle: choosing the suitable statin for complex risk profiles

Lowest is the best: reduction of LDL-C level and CV risk in ASCVD patients

Upfront lipid-lowering combination therapy in very high-risk patients: not a choice, a necessity

TBD

Meeting an unmet need: low-dose atorvastatin for Korean patients

Exploring the genetic landscape of CVD and diabetes: finding and future implication

Multi-omics and multi-trait analysis of metabolic disease

Recent progress in gene-targeting therapy for familial hypercholesterolemia

Metabolic disease promotes deoxyceramide accumulation in immune cells altering cytokine production

The role of digital health technology in managing atherosclerosis

Impact of lipid-lowering therapy on aortic aneurysm progression and cardiovascular outcomes

Remnant cholesterol as a residual risk in ASCVD patients under statin-based lipid-lowering therapy

Association between remnant cholesterol and sarcopenia: implications on muscle health

Targeting remnant cholesterol in the era of precision lipid management

2024 KSoLA consensus on secondary dyslipidemia

Understanding the progression of obesity-induced organ damage: Insights from the EAS staging system

Sex-specific gaps in lipid management and ASCVD

Advances in lipid-lowering therapy: shaping the future of cardiovascular prevention

Integrating ChatGPT into medical and clinical research workflows

Integrated management of hypertension and dyslipidemia for cardiovascular disease prevention

A new "standard" in dyslipidemia treatment

Recent trends and clinical evidence for optimizing lipid management

Closing the LDL-C gap in ASCVD: the role of siRNA therapy

Vascular tortuocity and atherosclerosis burden

Vessel wall enhancement and inflammation

Blood viscocity and intracranial atherosclerosis

Environmental pollution as a nontraditional risk factor for atherosclerotic cardiovascular disease: mechanisms and impacts

Health inequity as a nontraditional risk factor for ASCVD

Psychiatric disorders: an overlooked nontraditional risk factor in the development of atherosclerotic cardiovascular disease

Optimal LDL-C goals for secondary prevention in high-risk patients - a cardiologist’s perspective

Optimal LDL-C level for stroke prevention - insights from a neurologist’s perspective

Different LDL-C targets by duration of diabetes: what is the evidence? - an endocrinologist’s perspective

Multi-omics data integration from patients with carotid stenosis illuminates key molecular signatures of atherosclerotic instability

Bempedoic acid in real world practice, for whom?

Targeting APOC 3 for triglyceride management

ANGPTL3 and ANGPTL8 inhibition: novel strategies to combat atherogenic dyslipidemia

Triglyceride and HDL-C focus in Asian populations: rethinking priorities?

Combination lipid-lowering therapy: when statins alone are not enough

Ethnic differences in managing dyslipidemia: tailoring treatment strategies for Asian and Western populations

Biological and hormonal mechanisms linking sex and cardiometabolic risk

Sex and gender differences in risk assessment and biomarkers for cardiovascular disease

Do women and men respond differently to cardiometabolic therapies?

Glutamine homeostasis: an overlooked axis in cardiometabolic inflammation

Myeloid metabolism in the amplification and resolution of cardiac inflammation

Therapeutic promise of ANGPTL4 in cardiovascular inflammation

Benefits of atorvastatin / ezetimibe combination in diabetic dyslipidemia

FH vulnerability uncovered: why sustained LDL-C control matters

The lower the better: Rosuvastatin’s next option for dyslipidemia management

Safety and efficacy of moderate-intensity statin with ezetimibe in elderly patient with ASCVD

New approaches to treating hypertriglyceridemia in patients with renal impairment

Pravastatin’s effects on special populations

Comparative effectiveness of lercanidipine and amlodipine on MACE in hypertensive patients

Cumulative LDL-cholesterol burden and cardiovascular risk

Dyslipidemia in youth: why early intervention matters for lifelong cardiovascular health

Beyond LDL-C: role of ApoB and non-HDL cholesterol in early prevention

Strategies for managing hyperlipidemia in fragile elderly patients

Optimizing glucose control in fragile elderly patients with cardiometabolic syndrome

How to deal with multimorbidity and frailty for the prevention of cardiovascular disease

Anti-obesity effects of bioactive compound from natural products: a mechanism-oriented approach focusing on cellular signaling and metabolic regulation

Semaglutide for obesity treatment and cardiometabolic benefits

Tirzepatide a dual GIP GLP-1 receptor agonist in obesity and metabolic care

Cholesterol lowering throughout the life-course to prevent atherosclerotic cardiovascular disease-a pragmatic population health approach

The role of smooth muscle cell in atherosclerotic plaque progression

Cutting edge care of pitavastatin with ezetimibe combination therapy

Clinical efficacy of ultra-low-dose triple combination therapy (Amlodipine/Losartan/Chlorthalidone) in hypertension management

Reversing atherosclerosis - 20 years of data for CRESTOR

Gardens of Korea (한국의 정원)

Triglyceride metabolism, hypertriglyceridemia, and its therapeutics

Novel health functional products to prevent post-MI pathologic remodeling

Ultrasonicated Lespedeza cuneata extract prevents TNF-α-induced early atherosclerosis in vitro and in vivo

Regulation of mitochondrial metabolic reprogramming during aging

Atherosclerosis and lipid management in cancer survivors: balancing cardiovascular and oncologic risks

Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk equivalent

Atherosclerosis in chronic inflammatory diseases: focus on rheumatoid arthritis and systemic autoimmunity

Discrepant Effect of High-Density Lipoprotein Cholesterol on the Hematologic Malignancy Risk: A Nationwide Cohort Study

Cholesterol and Cardiovascular Risk in Type 2 Diabetes: The Role of Kidney Function

Association Between Lipoprotein (a) Levels and Coronary Artery Disease (CAD) Among Patients With or Without CAD Family History

Investigation of the Influence of Lipoprotein(a) and Oxidized Lipoprotein(a) on Plasminogen Activation and Fibrinolysis

Fatty Acids in Childhood Obesity: A Link Between Nutrition, Metabolic Alterations and Cardiovascular Risk

Managing dyslipidemia in women before and after menopause

Managing dyslipidemia in patients with liver disease

HIV, chronic inflammation, and dyslipidemia

Remnant cholesterol as a key contributor to atherosclerotic cardiovascular disease (ASCVD): mechanisms and clinical implications

The role of remnant cholesterol in chronic kidney disease (CKD)

Association between remnant cholesterol and dementia: potential mechanisms and clinical perspectives

Remnant cholesterol in women’s cardiometabolic health

IKKε-deficient macrophages impede cardiac repair after myocardial infarction by enhancing the macrophage-myofibroblast transition

Sensing ceramides by CYSLTR2 and P2RY6 to aggravate atherosclerosis

Targeting the USP35–FASN axis and choline metabolism in cancer: a lipidomics perspective

Recent update of coronary artery calcium scoring

The role of carotid ultrasonography for the primary prevention of cardiovascular disease

The usefulness of brachial-ankle PWV in the risk prediction for Asians